AJH: Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

Deletion and/or mutation of the TP53 gene is associated with short survival in multiple myeloma, but p53 is much more than that
.

At least 12 isoforms of p53 protein have been identified due to a combination of alternative splicing, alternative promoters, and/or alternative transcription site initiation sites, which are grouped into alpha, beta, gamma, transactivation domains (TA) ), long and short isomers

Deletion and/or mutation of the TP53 gene is associated with short survival in multiple myeloma, but p53 is much more than that

Figure 1: Schematic representation of human p53 protein isotypes, and the region containing the p53 antibody epitopes used in this study

Figure 1: Schematic representation of human p53 protein isotypes, and the region containing the p53 antibody epitopes used in this study

Currently, no studies have assessed the expression of p53 isoforms and their clinical relevance in multiple myeloma (MM)
.

The researchers used capillary nanoimmunoassay to quantify the expression of p53 protein isoforms in CD138 purified samples from 156 newly diagnosed MM patients treated as part of the PETHEMA/GEM2012 clinical trial and investigated their effect on prognosis.

Currently, no studies have assessed the expression of p53 isoforms and their clinical relevance in multiple myeloma (MM)

Figure 2: Association of p53 protein isoforms with 17p deletion and standard and high cytogenetic risk
.

Figure 2: Association of p53 protein isoforms with 17p deletion and standard and high cytogenetic risk
.

figure 2:

Quantitative real-time polymerase chain reaction was used to confirm the results at the RNA level
.

Low and high levels of expression of the short and TAp53β/γ isoforms, respectively, were associated with poor prognosis in MM patients

Quantitative real-time polymerase chain reaction was used to confirm the results at the RNA level

Figure 3: Progression-free survival and overall survival in MM patients according to the levels of p53 protein isoforms
.

Figure 3: Progression-free survival and overall survival in MM patients according to the levels of p53 protein isoforms
.

Figure 3: Progression-free survival and overall survival in MM patients according to the levels of p53 protein isoforms .

Current cytogenetic risk classifications are significantly improved when the expression levels of p53 protein isoforms are pooled, such that high-risk MM expressing high levels of short isoforms have significantly higher risk than high-risk patients with low levels of these isoforms.
longer survival time

Figure 4: Simultaneous effects of cytogenetic risk and p53 protein isoform levels on progression-free and overall survival in MM patients
.

Figure 4: Simultaneous effects of cytogenetic risk and p53 protein isoform levels on progression-free and overall survival in MM patients
.

This is the first study to demonstrate the prognostic value of p53 subtypes in MM patients
.

In conclusion, short and TAp53β/γ protein isoform expression was associated with clinical outcomes in MM patients, and prognostic stratification in MM patients was significantly improved when cytogenetic risk was combined with their expression levels

This is the first study to demonstrate the prognostic value of p53 subtypes in MM patients
.
In conclusion, short and TAp53β/γ protein isoform expression was associated with clinical outcomes in MM patients, and prognostic stratification in MM patients was significantly improved when cytogenetic risk was combined with their expression levels
.
These new findings broaden the range of known roles of p53 protein affecting MM outcome beyond the well-known adverse prognosis of TP53 gene deletion and/or mutation
.
In conclusion, short and TAp53β/γ protein isoform expression was associated with clinical outcomes in MM patients, and prognostic stratification in MM patients was significantly improved when cytogenetic risk was combined with their expression levels
.
These new findings broaden the range of known roles of p53 protein affecting MM outcome beyond the well-known adverse prognosis of TP53 gene deletion and/or mutation
.

 

Original source:

Original source:

Rojas, EA ,  Corchete, LA ,  De Ramón, C , et al.
  Expression of p53 protein isoforms predicts survival in patients with multiple myeloma .
  Am J Hematol .
  2022 ;  1-11 .
doi: 10.
1002  / ajh.
26507

Rojas, EA ,  Corchete, LA ,  De Ramón, C , et al.
  Expression of p53 protein isoforms predicts survival in patients with multiple myeloma .
  Am J Hematol .
  2022 ;  1-11 .
doi: 10.
1002  /ajh.
26507 Rojas , EA ,  Corchete, LA ,  De Ramón, C , et al.
  Expression of p53 protein isoforms predicts survival in patients with multiple myeloma .
  Am J Hematol .
  2022 ;  1-11 .
doi: 10.
1002  /ajh.
26507 Rojas , EA, Corchete, LA ,  De Ramón, C , et al.
  Expression of p53 protein isoforms predicts survival in patients with multiple myeloma .
  Am J Hematol .
2022  ; 1-11  .
doi : 

 

leave a message here